Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Effect of Once Daily Oral Vitamin D3 Supplementation on Inspiratory Muscle Strength in Vitamin D3-Deficient COPD Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02877641
• Other study ID #: I 240913
• Secondary ID: NCI-2016-00524I
• Status: Terminated
• Phase: Phase 2
• First received: August 17, 2016
• Last updated: February 14, 2017
• Start date: April 16, 2014
• Est. completion date: February 1, 2017

Study information

• Verified date: February 2017
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase IIb randomized trial studies how well cholecalciferol (vitamin D3) supplementation works in strengthening inspiratory muscles in cholecalciferol-deficient patients with chronic obstructive pulmonary disease (COPD). Cholecalciferol supplementation may help reduce the risk of developing lung cancer and strengthen the diaphragm in cholecalciferol-deficient patients with COPD.

Description:

PRIMARY OBJECTIVES:

I. To establish the effect of D vitamin (vitamin D3) supplementation on inspiratory muscle strength in vitamin D3-deficient chronic obstructive pulmonary disease (COPD) patients. (Roswell Park Cancer Institute [RPCI]/University at Buffalo [UB] study) II. To establish the 12 month conversion rate. (University of Pittsburgh Cancer Institute [UPCI] study)

SECONDARY OBJECTIVES:

I. To establish the effect of vitamin D3 supplementation on peripheral muscle strength and exercise capacity in vitamin D3-deficient COPD patients. (RPCI/UB study) II. To establish the 3 and 6-month conversion rates. (UPCI study) III. To examine whether vitamin D3 supplementation is equally effective in COPD patients who are current versus former smokers. (UPCI study)

TERTIARY OBJECTIVES:

I. To explore the effects of vitamin D3 supplementation in COPD patients on biomarkers of lung cancer risk, inflammation, and pulmonary function. (UPCI study)

OUTLINE: Patients are randomized to 1 of 2 arms.

CONTROL ARM: Patients receive a placebo and multivitamin orally (PO) once daily (QD) for 52 weeks.

SUPPLEMENTATION ARM: Patients receive a multivitamin and cholecalciferol supplement PO QD for 52 weeks.

After completion of study treatment, patients are followed up for 1 year.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: February 1, 2017
• Est. primary completion date: February 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Current or ex-smoker with at least a 10-year pack history

• COPD, defined as forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) < 70% and FEV1% predicted < 80%

• 25-hydroxy vitamin D3 (25[OH]D3) level less than 20 ng/mL prior to study initiation

• Willingness to comply with study guidelines

• Willingness to avoid alternative/additional vitamin D3 supplementation for the duration of the trial

• Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

• Personal history of lung cancer or head and neck cancer

• History of malabsorption syndrome (e.g., pancreatic insufficiency, celiac disease, or tropical sprue)

• History of known thyroid disease

• History of known sarcoid disease

• History of known abnormalities in calcium metabolism

• Hypercalcemia (serum calcium in excess of laboratory upper limit normal [ULN])

• Self-reported consumption of more than 4 alcoholic drinks per day

• Use of anti-seizure medications phenobarbital or phenytoin, which can disrupt vitamin D metabolism

• History of known renal dysfunction

• History of known nephrolithiasis (kidney stones)

• Current use of supplemental oxygen

• Inability to exercise due to musculoskeletal issue, osteoarthritis or underlying cardiac disease

• Current participation in a cancer intervention prevention study, except for smoking cessation

• Any condition which in the Investigator's opinion deems the subject an unsuitable candidate to receive study drug

• Inability to swallow pills

• Vitamin D supplementation > 2,000 IU/day of vitamin D within 30 days prior to enrollment

• Positive Pregnancy Test

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Muscle Weakness
• Paresis
• Pulmonary Disease, Chronic Obstructive

Intervention

Dietary Supplement:
• Cholecalciferol
Given PO

Other:
• Laboratory Biomarker Analysis
Correlative studies

Dietary Supplement:
• Multivitamin
Given PO

Other:
• Placebo
Given PO
• Questionnaire Administration
Ancillary studies

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (2)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in correlative biomarkers of lung cancer risk, inflammation, and pulmonary function (UPCI study)	The vitamin D3 supplementation group will be compared to the placebo control group using two-sample t-tests at each time point for preliminary analysis. The correlation between muscle strength and the correlative biomarkers will be explored using Pearson correlation.	Baseline to up to 1 year
Primary	Conversion rate, defined as the proportion of patients whose baseline cholecalciferol deficiency is corrected (UPCI study)	75% will be considered a success.	At 12 months
Primary	Inspiratory muscle strength assessed by respiratory capacity (RPCI/UB study)	Will be analyzed using linear mixed model by regressing the repeated outcome on the group indicator (treatment or control) and other appropriate covariates. Appropriate within-subject covariance will be determined from an exploratory study. The effect of vitamin D3 supplementation will be tested using an approximate t-test.	Baseline to 24 weeks
Secondary	Change in exercise capacity assessed by respiratory exercise tests (RPCI/UB study)	Peak oxygen consumption will be used to establish cardiovascular fitness. Breath-by-breath measurements of minute ventilation, tidal volume, breathing frequency, end tidal carbon dioxide, carbon dioxide production and oxygen consumption will be continuously measured.	Baseline to 24 weeks
Secondary	Change in peripheral muscle strength assessed by the elbow flexion test (RPCI/UB study)	The elbow flexion test (upper extremity) requires participants to curl a standard 8 lb weight as many times as possible in a 30 second time period.	Baseline to 24 weeks
Secondary	Conversion rate, defined as the proportion of patients whose baseline cholecalciferol deficiency is corrected (UPCI study)	Efficacy in in COPD patients who are current versus former smokers will be compared.	At 3 months
Secondary	Conversion rate, defined as the proportion of patients whose baseline cholecalciferol deficiency is corrected (UPCI study)	Efficacy in in COPD patients who are current versus former smokers will be compared.	At 6 months
Secondary	Change in peripheral muscle strength assessed by squat test (RPCI/UB study)	This functional sit-to-stand test measures lower extremity strength. Participants will perform as many sit-to-stand repetitions from a standard height chair in 60 seconds as possible.	Baseline to 24 weeks